摘要
目的研究经基因重组人生长激素治疗不同骨龄的特发性身材矮小儿童的临床疗效。方法选取2021年8月-2022年10月在我院诊治的60例特发性身材矮小儿童为研究对象,依据骨龄分为对照1组(5~8岁,n=30)和对照2组(9~12岁,n=30),均给予基因重组人生长激素治疗,比较两组临床疗效、生长相关指标(身高、胰岛素样生长因子-1)、骨代谢指标(骨密度、骨钙素)及不良反应发生率。结果对照1组治疗总有效率为93.33%,高于对照2组的83.33%(P<0.05);两组治疗后身高、胰岛素样生长因子-1水平均高于治疗前,且对照1组高于对照2组(P<0.05);两组治疗后骨密度、骨钙素水平均高于治疗前,且对照1组高于对照2组(P<0.05);对照1组不良反应发生率为6.67%,低于对照2组的16.67%(P<0.05)。结论经基因重组人生长激素治疗不同骨龄的特发性身材矮小儿童临床疗效存在差异,相对而言低骨龄(5~8岁)患儿的治疗效果更为突出,身高、骨代谢指标均改善,且不良反应发生率低,值得临床应用。
Objective To study the clinical efficacy of recombinant human growth hormone in the treatment of idiopathic short stature children with different bone ages.Methods Sixty children with idiopathic short stature diagnosed and treated in our hospital from August 2021 to October 2022 were selected as the research objects.According to bone age,they were divided into control group 1(5-8 years old,n=30)and control group 2(9-12 years old,n=30).Both groups were treated with recombinant human growth hormone.The clinical efficacy,growth-related indicators(height,insulin-like growth factor-1),bone metabolism indicators(bone mineral density,osteocalcin)and incidence of adverse reactions were compared between the two groups.Results The total effective rate of treatment in the control group 1 was 93.33%,which was higher than 83.33%in the control group 2(P<0.05).After treatment,the height and insulin-like growth factor-1 levels in the two groups were higher than those before treatment,and those in the control group 1 were higher than those in the control group 2(P<0.05).After treatment,the bone mineral density and osteocalcin levels in the two groups were higher than those before treatment,and those in the control group 1 were higher than those in the control group 2(P<0.05).The incidence of adverse reactions in the control group 1 was 6.67%,which was lower than 16.67%in the control group 2(P<0.05).Conclusion The clinical efficacy of recombinant human growth hormone in the treatment of idiopathic short stature children with different bone ages is different.Relatively speaking,the treatment effect of children(5-8 years old)with low bone age is more prominent,and the height and bone metabolism indexes are improved,and the incidence of adverse reactions is low,which is worthy of clinical application.
作者
曾小莲
吴艳花
刘荣昌
ZENG Xiao-lian;WU Yan-hua;LIU Rong-chang(Department of Pediatrics,People's Hospital of Shangyou County,Shangyou 341200,Jiangxi,China)
出处
《医学信息》
2023年第20期125-128,共4页
Journal of Medical Information
基金
江西省赣州市指导性科技计划项目(编号:GZ2021ZSF427)。
